Develops therapies for neurodegenerative diseases, focusing on treatments for Alzheimer's and Parkinson's diseases.
NeuroBo Pharmaceuticals, Inc. is a dynamic clinical-stage biotechnology firm based in Boston, Massachusetts, dedicated to advancing multimodal disease-modifying therapies across a spectrum of viral, neuropathic, and neurodegenerative conditions. At the forefront of its innovative pipeline is ANA001, an exclusive oral niclosamide formulation designed specifically to combat moderate COVID-19 infections. Additionally, NeuroBo is actively developing NB-01, aimed at alleviating the symptoms of painful diabetic neuropathy, and NB-02, which targets cognitive impairment and seeks to slow the progression of neurodegenerative diseases linked to tau protein dysfunction. The company's diverse portfolio also includes Gemcabene, explored for multiple indications, including its potential synergy with ANA001 in COVID-19 treatment.
Founded with a mission to redefine treatment paradigms through cutting-edge research and development, NeuroBo Pharmaceuticals continues to expand its therapeutic footprint with a focus on addressing unmet medical needs. By leveraging strategic partnerships and fostering a culture of innovation, NeuroBo aims to deliver impactful therapies that enhance patient outcomes and quality of life. The company's commitment to scientific excellence and patient-centric care underscores its role as a leading innovator in the biotechnology sector.
Since its inception, NeuroBo Pharmaceuticals has rapidly emerged as a pivotal player in biopharmaceutical innovation, driven by a passionate team of researchers and industry experts. With a robust pipeline and a strong foundation in Boston's biotech hub, NeuroBo remains dedicated to advancing novel therapies that not only treat but potentially modify the course of debilitating diseases, paving the way for a healthier future worldwide.